Evotec and Beyond Batten Disease Foundation Collaborate to Advance Emerging Therapies to Fight Juvenile Batten Disease

HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
today announced an EVT Execute collaboration with Beyond Batten Disease
Foundation (“BBDF”) aimed at discovering and developing new treatments
for juvenile Batten disease, a rare, fatal autosomal recessive
neurodegenerative disorder.

Under the terms of the agreement, Evotec will develop and use in vivo
mechanistic and efficacy assays to assess the translational potential of
fundamental and early drug discovery findings emerging from academic
institutions in the United States and Europe. The goal of this programme
is to leverage Evotec’s broad discovery expertise and experience to
validate findings and to initiate their translation from bench to
bedside. Evotec joins a dynamic, multidisciplinary pipeline of
foundation-led activity designed to prioritise therapeutically promising
findings while de-emphasising programmes that under-perform in the
translational space. The collaboration includes substantial research
funding to Evotec and runs to the end of 2017, with an option to extend
beyond this period.

Further financial details were not disclosed.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are
pleased to welcome Beyond Batten Disease Foundation as a new partner and
join in the effort to develop therapies against this rare disease. We
are confident that with our world-leading drug discovery platform and
expertise significant progress can be made in this programme and

Craig Benson, BBDF Founder and Chairman of the Board added: “BBDF is
delighted to be partnering with a global industry leader like Evotec to
further our mission to eradicate juvenile Batten disease. Our goal is to
leverage their expertise to advance our research into clinical trials,
and ultimately a treatment, as quickly as possible.”


Juvenile Batten (CLN3) disease is a rare, fatal, inherited disorder of
the nervous system that usually begins in childhood. The first symptom
is usually progressive vision loss in previously healthy children
followed by personality changes, behavioural problems and slowed
learning. Seizures and psychosis can begin at any time during the course
of disease. Progressive loss of motor functions (movement and speech)
start with clumsiness, stumbling and Parkinson-like symptoms.
Eventually, those affected become wheelchair-bound are bedridden and die


Beyond Batten Disease Foundation (“BBDF”) is the world’s largest
organisation dedicated to funding research for a treatment or cure for
juvenile Batten (CLN3) disease. Since its inception in 2008, BBDF has
applied over $ 15.5 m. BBDF is spearheading a unique, cohesive strategy,
incorporating independent scientific resources and collaboration with
related organizations to drive research in juvenile Batten Disease. For
more information, visit www.beyondbatten.org.


Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with
leading pharmaceutical and biotechnology companies, academics, patient
advocacy groups and venture capitalists. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has
established a unique position by assembling top-class scientific experts
and integrating state-of-the-art technologies as well as substantial
experience and expertise in key therapeutic areas including
neuroscience, pain, metabolic diseases as well as oncology, inflammation
and infectious diseases. Evotec has long-term discovery alliances with
partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the
Company has existing development partnerships and product candidates
both in clinical and pre-clinical development. These include
partnerships with Boehringer Ingelheim and MedImmune in the field of
diabetes, with Janssen Pharmaceuticals in the field of depression and
with Roche in the field of Alzheimer’s disease. For additional
information please go to www.evotec.com.


Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates
or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on
which any such statement is based.

Language: English

Company: Evotec AG

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg Germany

Phone: +49 (0)40 560 81-0

Fax: +49 (0)40 560 81-222

E-mail: info@evotec.com

Internet: www.evotec.com

ISIN: DE0005664809

WKN: 566480

Indices: TecDAX Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart


Evotec AG
Gabriele Hansen
VP Corporate Communications &
Investor Relations
Phone: +49.(0)40.56081-255